Drug Prices
Total reimbursement for brand-name prescription drugs in Medicare Part D increased 77% between 2011 and 2015, nearly six times faster than inflation, despite a 17% decrease in the number of prescriptions.
The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
AHA today urged the Health Resources and Services Administration to implement without further delay its final regulation on 340B drug ceiling prices and civil monetary penalties for manufacturers.
Medicare D prescription drug plan should not prevent pharmacies from telling customers when they could pay less for a drug by paying cash, the Centers for Medicare & Medicaid Services told plan sponsors yesterday.
House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices.
The Centers for Medicare & Medicaid Services today updated the Parts B and D drug spending dashboards with 2016 information.
The Senate Health, Education, Labor and Pensions Committee today held the second in a series of hearings examining the 340B drug savings program.
The Department of Health and Human Services, May 14, issued a policy statement and request for information (RFI) on ways to lower drug prices and reduce out-of-pocket costs for consumers.
Health and Human Services Secretary Alex Azar today provided additional information on steps the agency will take to implement the president’s blueprint to lower prescription drug costs.
Another week, another drug industry-funded consultant attempting to divert attention away from the high and rising costs of prescription drugs by attacking the 340B drug pricing program.